Business Context and Reporting Period
This Form 8-K reports on the 2021 Annual Meeting of Stockholders held by NanoViricides, Inc. on November 20, 2021. The company is incorporated in Nevada and its common stock trades on the NYSE American under the symbol NNVC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders representing 60.7% of the voting capital stock participated in the meeting. The following proposals were approved:
- Director Election: Anil Diwan was re-elected as a Class I Director for a two-year term.
- Executive Compensation Vote: Stockholders approved an advisory vote on executive compensation to occur every three years.
- Equity Grant: Stockholders approved an award of 10,204 Series A Convertible Preferred Shares to Anil Diwan in connection with the extension of his employment as President.
- Auditor Ratification: The appointment of EisnerAmper, LLP as the independent registered public accounting firm for the fiscal year ending June 30, 2022, was ratified.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. Detailed descriptions of the proposals are referenced in the Proxy Statement filed on October 12, 2021.
Investor Verification Checklist
- Verify the terms of the employment extension for Anil Diwan associated with the 10,204 Series A Preferred Shares grant.
- Review the October 12, 2021 Proxy Statement for detailed rationale behind the executive compensation advisory vote interval.
- Confirm the impact of the Series A Preferred Shares grant on the company's capital structure and potential dilution.
- Check subsequent filings for the company's financial performance for the fiscal year ending June 30, 2022, as audited by EisnerAmper, LLP.